



SUPPLEMENTARY MATERIAL

DOI: [10.4081/monaldi.2021.1679](https://doi.org/10.4081/monaldi.2021.1679)

Effectiveness and safety of fully oral modified shorter treatment regimen for multidrug-resistant tuberculosis in Georgia, 2019-2020

**Teona Avaliani¹, Yuliia Sereda², Hayk Davtyan³, Nestani Tukvadze¹,
Tamar Togonidze¹, Nana Kiria¹, Olga Denisiuk⁴, Ogtay Gozalov², Sevim Ahmedov⁵,
Arax Hovhannesian²**

¹National Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia; ²World Health Organization Regional Office for Europe, Copenhagen, Denmark; ³Tuberculosis Research and Prevention Center, Yerevan, Armenia; ⁴Alliance for Public Health, Kyiv, Ukraine; ⁵United States Agency for International Development, Washington DC, USA

Correspondence: Teona Avaliani, National Center for Tuberculosis and Lung Diseases, 8 Achara str, Tbilisi 0101, Georgia. Tel. +995.593 48 89 65. E-mail: teoavaliani1@gmail.com

Key words: MDR-TB; modified all-oral shorter treatment regimen; rifampicin resistance; time to culture conversion; adverse drug safety monitoring.

Supplementary Table 1. Dosage of drugs used for the standards modified short treatment regimen in RR/MDR-TB patients in Georgia, 2019-2020.

Supplementary Table 1. Dosage of drugs used for the standards modified short treatment regimen in RR/MDR-TB patients in Georgia, 2019-2020.

Drug	Drug doses by weight band of adult patients				
	30-35 kg	36-45 kg	46-55 kg	56-70 kg	>70 kg
Bedaquiline (Bdq)	400 mg for first 2 weeks; then 200 mg 3 times a week				
Linezolid (Lzd)	300 mg	300 mg	600 mg	600 mg	600 mg
Levofloxacin (Lx)	750 mg	750 mg	1000 mg	1000 mg	1000 mg
Clofazimine (Cfz)	100 mg	100 mg	100 mg	100 mg	100 mg
Cycloserine (Cs)	500 mg	500 mg	750 mg	750 mg	750 mg
Delamanid (Dlm)	200 mg	200 mg	200 mg	200 mg	200 mg

Creative Commons Attribution 3.0 IGC